Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings

News
1

https://globenewswire.com/news-release/2018/11/15/1652262/0/en/Minerva-Neurosciences-to-Host-Roluperidone-Update-and-Key-Opinion-Leader-Discussion-of-Negative-Symptoms-in-CNS-Psychiatric-Diseases-on-November-20-2018.html

Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in CNS/psychiatry diseases.

1 Like
2

I wonder what we’d all be like if we had significant improvement in our negative symptoms. :thinking:

2 Likes
3

Roluperidone should be good, the D2 thing really leads to a lot of issues. If we can get a med out there which doesn’t cause issues associated with that, calms fown the brain (somehow) and helps ppl sleep consistently and with good sleep architecture it will free people w/diff. types of MI.

1 Like